Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics Inc
(NQ:
VTGN
)
3.840
-0.070 (-1.79%)
Official Closing Price
Updated: 4:15 PM EDT, Jul 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vistagen Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes PH94B PALISADE-1 Phase 3 Clinical Study for Acute Treatment of SAD
June 22, 2022
Via
Investor Brand Network
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
June 22, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Webcast to Announce FY 2022 Results
June 17, 2022
Via
Investor Brand Network
VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
June 17, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Present Clinical Trial Abstract at ASCP Annual Meeting
June 02, 2022
Via
Investor Brand Network
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
June 02, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Top Investor Conferences
May 27, 2022
Via
Investor Brand Network
VistaGen to Participate in Upcoming June Investor Conferences
May 27, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Names New Chief Legal Officer
May 02, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
VistaGen Appoints Reid Adler as Chief Legal Officer
May 02, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Slated to Report Preclinical Data on Lead Candidate at Upcoming Scientific Congresses
April 21, 2022
Via
Investor Brand Network
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
April 21, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), AffaMed Announce Substantial Progress Toward Initiating PALISADE Global Trial
April 12, 2022
Via
Investor Brand Network
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
April 12, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Maxim Group 2022 Virtual Growth Conference
March 24, 2022
Via
Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2022 Financial Numbers, Corporate Update
February 11, 2022
Via
Investor Brand Network
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Release FY 2022 Q3 Financial Results, Host Conference Call
February 07, 2022
Via
Investor Brand Network
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at the Jefferies London Healthcare Conference on November 18
November 16, 2021
Via
Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2022 Financial Numbers, Corporate Highlights
November 11, 2021
Via
Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Call, Release Q2 2022 Financial Report and Development Update
November 04, 2021
Via
Investor Brand Network
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
October 14, 2021
Via
Investor Brand Network
Exposures
COVID-19
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity
October 05, 2021
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.